WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2023)
Top biotech stocks in 2023 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Dividends Score
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC
$641.89MN/A0.00%N/AN/AN/AN/A
VYGR
VOYAGER THERAPEUTICS INC
$345.80MN/A0.00%N/AN/AN/AN/A
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$1.82BN/A0.00%N/AN/AN/AN/A
GMAB
GENMAB A
$21.38BN/A0.00%N/AN/AN/AN/A
AMLX
AMYLYX PHARMACEUTICALS INC
$960.10MN/A0.00%N/AN/AN/AN/A
ZYME
ZYMEWORKS INC
$668.52MN/A0.00%N/AN/AN/AN/A
MEIP
MEI PHARMA INC
$44.84M26.00%0.00%$1.7500$1.7599%0
CPRX
CATALYST PHARMACEUTICALS INC
$1.53BN/A0.00%N/AN/AN/AN/A
INCY
INCYTE CORP
$12.37BN/A0.00%N/AN/AN/AN/A
FBIO
FORTRESS BIOTECH INC
$29.51MN/A0.00%N/AN/AN/AN/A
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
$1.30BN/A0.00%N/AN/AN/AN/A
UTHR
UNITED THERAPEUTICS CORP
$11.38BN/A0.00%N/AN/AN/AN/A
HALO
HALOZYME THERAPEUTICS INC
$5.30BN/A0.00%N/AN/AN/AN/A
BMRN
BIOMARIN PHARMACEUTICAL INC
$17.88BN/A0.00%N/AN/AN/AN/A
LGND
LIGAND PHARMACEUTICALS INC
$1.07BN/A0.00%N/AN/AN/AN/A
OCUP
OCUPHIRE PHARMA INC
$64.06MN/A0.00%N/AN/AN/AN/A
VNDA
VANDA PHARMACEUTICALS INC
$228.40MN/A0.00%N/AN/AN/AN/A
MRKR
MARKER THERAPEUTICS INC
$25.07MN/A0.00%N/AN/AN/AN/A
EXEL
EXELIXIS INC
$6.84BN/A0.00%N/AN/AN/AN/A
MGNX
MACROGENICS INC
$553.92MN/A0.00%N/AN/AN/AN/A
SPRO
SPERO THERAPEUTICS INC
$66.78MN/A0.00%N/AN/AN/AN/A
TECH
BIO-TECHNE CORP
$10.76B0.47%20.50%$0.0800$0.326%1
OBIO
ORCHESTRA BIOMED HOLDINGS INC
$268.44MN/A0.00%N/AN/AN/AN/A
PBYI
PUMA BIOTECHNOLOGY INC
$198.85MN/A0.00%N/AN/AN/AN/A
VERV
VERVE THERAPEUTICS INC
$823.05MN/A0.00%N/AN/AN/AN/A
CLGN
COLLPLANT BIOTECHNOLOGIES LTD
$61.27MN/A0.00%N/AN/AN/AN/A
ORTX
ORCHARD THERAPEUTICS PLC
$370.55MN/A0.00%N/AN/AN/AN/A
AGIO
AGIOS PHARMACEUTICALS INC
$1.29BN/A0.00%N/AN/AN/AN/A
CRNX
CRINETICS PHARMACEUTICALS INC
$2.24BN/A0.00%N/AN/AN/AN/A
CRSP
CRISPR THERAPEUTICS AG
$5.58BN/A0.00%N/AN/AN/AN/A
NRBO
NEUROBO PHARMACEUTICALS INC
$19.76MN/A0.00%N/AN/AN/AN/A
PRTA
PROTHENA CORP PUBLIC LTD CO
$2.03BN/A0.00%N/AN/AN/AN/A
SEER
SEER INC
$106.59MN/A0.00%N/AN/AN/AN/A
YMAB
Y-MABS THERAPEUTICS INC
$298.81MN/A0.00%N/AN/AN/AN/A
RNA
AVIDITY BIOSCIENCES INC
$596.52MN/A0.00%N/AN/AN/AN/A
FUSN
FUSION PHARMACEUTICALS INC
$415.61MN/A0.00%N/AN/AN/AN/A
NRIX
NURIX THERAPEUTICS INC
$414.71MN/A0.00%N/AN/AN/AN/A
CORT
CORCEPT THERAPEUTICS INC
$2.76BN/A0.00%N/AN/AN/AN/A
PLX
PROTALIX BIOTHERAPEUTICS INC
$124.02MN/A0.00%N/AN/AN/AN/A
ALLO
ALLOGENE THERAPEUTICS INC
$424.06MN/A0.00%N/AN/AN/AN/A
LPCN
LIPOCINE INC
$13.84MN/A0.00%N/AN/AN/AN/A
PLUR
PLURI INC
$25.39MN/A0.00%N/AN/AN/AN/A
LIFE
ATYR PHARMA INC
$70.86MN/A0.00%N/AN/AN/AN/A
AXSM
AXSOME THERAPEUTICS INC
$3.32BN/A0.00%N/AN/AN/AN/A
REGN
REGENERON PHARMACEUTICALS INC
$92.52BN/A0.00%N/AN/AN/AN/A
DNLI
DENALI THERAPEUTICS INC
$2.59BN/A0.00%N/AN/AN/AN/A
PGEN
PRECIGEN INC
$291.24MN/A0.00%N/AN/AN/AN/A
LUMO
LUMOS PHARMA INC
$23.03MN/A0.00%N/AN/AN/AN/A
CRMD
CORMEDIX INC
$195.68MN/A0.00%N/AN/AN/AN/A
DNTH
DIANTHUS THERAPEUTICS INC
$156.92MN/A0.00%N/AN/AN/AN/A
STOK
STOKE THERAPEUTICS INC
$205.41MN/A0.00%N/AN/AN/AN/A
ENTX
ENTERA BIO LTD
$19.02MN/A0.00%N/AN/AN/AN/A
LXRX
LEXICON PHARMACEUTICALS INC
$306.16MN/A0.00%N/AN/AN/AN/A
KNSA
KINIKSA PHARMACEUTICALS LTD
$1.25BN/A0.00%N/AN/AN/AN/A
ADMA
ADMA BIOLOGICS INC
$851.90MN/A0.00%N/AN/AN/AN/A
BLUE
BLUEBIRD BIO INC
$525.91MN/A0.00%N/AN/AN/AN/A
SYRS
SYROS PHARMACEUTICALS INC
$98.17MN/A0.00%N/AN/AN/AN/A
APRE
APREA THERAPEUTICS INC
$13.73MN/A0.00%N/AN/AN/AN/A
VRTX
VERTEX PHARMACEUTICALS INC
$91.21BN/A0.00%N/AN/AN/AN/A
PALI
PALISADE BIO INC
$5.63MN/A0.00%N/AN/AN/AN/A
ZLAB
ZAI LAB LTD
$2.72BN/A0.00%N/AN/AN/AN/A
ALT
ALTIMMUNE INC
$353.54MN/A0.00%N/AN/AN/AN/A
ATAI
ATAI LIFE SCIENCES NV
$194.23MN/A0.00%N/AN/AN/AN/A
KRON
KRONOS BIO INC
$74.06MN/A0.00%N/AN/AN/AN/A
IGMS
IGM BIOSCIENCES INC
$408.76MN/A0.00%N/AN/AN/AN/A
DBVT
DBV TECHNOLOGIES SA
$152.14MN/A0.00%N/AN/AN/AN/A
BGNE
BEIGENE LTD
$18.78BN/A0.00%N/AN/AN/AN/A
STRO
SUTRO BIOPHARMA INC
$207.85MN/A0.00%N/AN/AN/AN/A
TGTX
TG THERAPEUTICS INC
$2.43BN/A0.00%N/AN/AN/AN/A
CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC
$6.04MN/A0.00%N/AN/AN/AN/A
SPRB
SPRUCE BIOSCIENCES INC
$59.03MN/A0.00%N/AN/AN/AN/A
CBAY
CYMABAY THERAPEUTICS INC
$2.47BN/A0.00%N/AN/AN/AN/A
VRNA
VERONA PHARMA PLC
$1.09BN/A0.00%N/AN/AN/AN/A
IMRX
IMMUNEERING CORP
$239.13MN/A0.00%N/AN/AN/AN/A
RNAC
CARTESIAN THERAPEUTICS INC
$125.25MN/A0.00%N/AN/AN/AN/A
IMGN
IMMUNOGEN INC
$7.82BN/A0.00%N/AN/AN/AN/A
TCRT
ALAUNOS THERAPEUTICS INC
$14.44MN/A0.00%N/AN/AN/AN/A
CRVO
CERVOMED INC
$49.99MN/A0.00%N/AN/AN/AN/A
RYTM
RHYTHM PHARMACEUTICALS INC
$2.25BN/A0.00%N/AN/AN/AN/A
KTTA
PASITHEA THERAPEUTICS CORP
$6.86MN/A0.00%N/AN/AN/AN/A
CGEN
COMPUGEN LTD
$71.12MN/A0.00%N/AN/AN/AN/A
ANIX
ANIXA BIOSCIENCES INC
$111.85MN/A0.00%N/AN/AN/AN/A
ABSI
ABSCI CORP
$220.26MN/A0.00%N/AN/AN/AN/A
MRNS
MARINUS PHARMACEUTICALS INC
$462.24MN/A0.00%N/AN/AN/AN/A
SAGE
SAGE THERAPEUTICS INC
$1.25BN/A0.00%N/AN/AN/AN/A
ONTX
ONCONOVA THERAPEUTICS INC
$13.17MN/A0.00%N/AN/AN/AN/A
CMRX
CHIMERIX INC
$86.49MN/A0.00%N/AN/AN/AN/A
TBPH
THERAVANCE BIOPHARMA INC
$527.86MN/A0.00%N/AN/AN/AN/A
FULC
FULCRUM THERAPEUTICS INC
$306.64MN/A0.00%N/AN/AN/AN/A
LYEL
LYELL IMMUNOPHARMA INC
$488.63MN/A0.00%N/AN/AN/AN/A
MIRM
MIRUM PHARMACEUTICALS INC
$1.50BN/A0.00%N/AN/AN/AN/A
VCYT
VERACYTE INC
$1.83BN/A0.00%N/AN/AN/AN/A
KRYS
KRYSTAL BIOTECH INC
$2.92BN/A0.00%N/AN/AN/AN/A
MIST
MILESTONE PHARMACEUTICALS INC
$99.11MN/A0.00%N/AN/AN/AN/A
VRCA
VERRICA PHARMACEUTICALS INC
$168.68MN/A0.00%N/AN/AN/AN/A
XCUR
EXICURE INC
$3.48MN/A0.00%N/AN/AN/AN/A
FRTX
FRESH TRACKS THERAPEUTICS INC
$5.47MN/A0.00%N/AN/AN/AN/A
IMMP
IMMUTEP LTD
$245.77MN/A0.00%N/AN/AN/AN/A
BCYC
BICYCLE THERAPEUTICS PLC
$666.44MN/A0.00%N/AN/AN/AN/A
SPRY
ARS PHARMACEUTICALS INC
$501.11MN/A0.00%N/AN/AN/AN/A

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Dec 2023?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Arcturus Therapeutics Holdings (NASDAQ:ARCT)


Arcturus Therapeutics Holdings (NASDAQ:ARCT) is the top biotech stock with a Zen Score of 75, which is 49 points higher than the biotech industry average of 26. It passed 24 out of 33 due diligence checks and has strong fundamentals. Arcturus Therapeutics Holdings has seen its stock return 34.72% over the past year, overperforming other biotech stocks by 59 percentage points.

Arcturus Therapeutics Holdings has an average 1 year price target of $58.67, an upside of 144.24% from Arcturus Therapeutics Holdings's current stock price of $24.02.

Arcturus Therapeutics Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Arcturus Therapeutics Holdings, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second best biotech stock with a Zen Score of 66, which is 40 points higher than the biotech industry average of 26. It passed 21 out of 33 due diligence checks and has strong fundamentals. Voyager Therapeutics has seen its stock return 34.36% over the past year, overperforming other biotech stocks by 58 percentage points.

Voyager Therapeutics has an average 1 year price target of $16.00, an upside of 103.56% from Voyager Therapeutics's current stock price of $7.86.

Voyager Therapeutics stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Voyager Therapeutics, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the third best biotech stock with a Zen Score of 64, which is 38 points higher than the biotech industry average of 26. It passed 21 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -48.27% over the past year, underperforming other biotech stocks by -24 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $48.71, an upside of 56.89% from Harmony Biosciences Holdings's current stock price of $31.05.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Harmony Biosciences Holdings, 57.14% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 14.29% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Kineta (NASDAQ:KA)


Kineta (NASDAQ:KA) has an annual dividend yield of 223.94%, which is 183 percentage points higher than the biotech industry average of 40.78%.

Kineta's dividend payout ratio of -16,683.3% indicates that its high dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 26%, which is -15 percentage points lower than the biotech industry average of 40.78%.

Mei Pharma's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

3. Gyre Therapeutics (NASDAQ:GYRE)


Gyre Therapeutics (NASDAQ:GYRE) has an annual dividend yield of 18.38%, which is -22 percentage points lower than the biotech industry average of 40.78%. Gyre Therapeutics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Gyre Therapeutics's dividend has not shown consistent growth over the last 10 years.

Gyre Therapeutics's dividend payout ratio of -17.4% indicates that its high dividend yield might not be sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 0.99% in the last day, and up 5.13% over the last week. Cerevel Therapeutics Holdings was the among the top gainers in the biotechnology industry, gaining 11.37% yesterday.

Cerevel Therapeutics shares are trading higher after AbbVie announced it will acquire the company for a total equity value of approximately $8.7 billion.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 70 points higher than the biotech industry average of 30. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 34.36% in the past year. It has overperformed other stocks in the biotech industry by 58 percentage points.

2. Arcturus Therapeutics Holdings (NASDAQ:ARCT)


Arcturus Therapeutics Holdings (NASDAQ:ARCT) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Arcturus Therapeutics Holdings has a valuation score of 100, which is 70 points higher than the biotech industry average of 30. It passed 7 out of 7 valuation due diligence checks.

Arcturus Therapeutics Holdings's stock has gained 34.72% in the past year. It has overperformed other stocks in the biotech industry by 59 percentage points.

3. Fortress Biotech (NASDAQ:FBIO)


Fortress Biotech (NASDAQ:FBIO) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Fortress Biotech has a valuation score of 100, which is 70 points higher than the biotech industry average of 30. It passed 7 out of 7 valuation due diligence checks.

Fortress Biotech's stock has dropped -66.67% in the past year. It has underperformed other stocks in the biotech industry by -43 percentage points.

Are biotech stocks a good buy now?

51.29% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 88.31% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 11.53x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.